Insulin efsitora alfa

Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR) . Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes[1].

Product Specifications

CAS Number

[2131038-11-2]

Product Name Alternative

LY-3209590

UNSPSC

12352203

Target

Insulin Receptor

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/insulin-efsitora-alfa.html

Purity

99.80

Solubility

10 mM in DMSO

Smiles

[Insulinefsitoraalfa]

Molecular Weight

(64.1 kDa)

References & Citations

[1]Heise T, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023 Apr;25 (4) :1080-1090. |[2]Moyers JS, et al. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. J Pharmacol Exp Ther. 2022 Sep;382 (3) :346-355.